Last updated: February 15, 2026
Development Update and Market Projection for Basmisanil
Basmisanil (INN), also known by research identifiers RG1662 and RO5186582, is a selective negative allosteric modulator of the alpha-5 subtype of GABA-A receptors. Its primary focus has been on cognitive impairments associated with neurodevelopmental and neurodegenerative disorders.
Development Status
Clinical Trials and Regulatory Progress
- Phase 2 Trials: Basmisanil has been evaluated in multiple phase 2 trials primarily targeting cognitive deficits in neurodevelopmental disorders such as Down syndrome (DS). These trials have assessed safety, tolerability, and preliminary efficacy.
- Key Study Outcomes: Results from the TRixie trial (NCT02602757) reported in 2018 indicated that Basmisanil did not meet primary endpoints for cognitive improvement in children with DS.
- Regulatory Status: No current approvals; ongoing or planned trials are unverified as of late 2023. The developer, Roche (Genentech), shifted focus after limited efficacy signals.
Development Challenges
- Failure to Demonstrate Efficacy: Despite targeting GABAergic dysfunction, clinical trials did not show significant cognitive benefits.
- Market Withdrawal: Roche discontinued development for DS-related indications following phase 2 results.
- Ongoing Research: The compound may still be studied for other indications or through partnerships, but no major trials are publicly announced.
Intellectual Property
- Roche has patent protections on Basmisanil until around 2030, potentially extending if patent term extensions are applied.
Market Projection
Potential Indications and Market Size
- Initial Target: Cognitive impairment in Down syndrome, with a market size estimated at approximately $1.5 billion globally.
- Secondary Uses: Other neuropsychiatric conditions (e.g., schizophrenia, aged-related cognitive decline) are speculative, with no active development.
Competitive Landscape
- Basmisanil competes with other GABA-A receptor modulators and cognitive enhancers.
- Notable competitors include drugs targeting NMDA receptors, cholinesterase inhibitors, and novel neuroplasticity agents.
Commercial Outlook
- Post-Trial Insights: Given clinical trial failures, Roche has deprioritized Basmisanil for DS. The likelihood of commercialization diminishes unless new partner interest arises.
- Potential Market Entry: If repositioned for other indications, niche markets in neurodegenerative or psychiatric disorders could emerge, but no clear pipeline exists.
Market Dynamics and Future Opportunities
- Derivative compounds or enhanced formulations could resurrect prospects if efficacy signals are observed in other contexts.
- Emerging data on GABAergic modulation in neurodegeneration may influence future research directions.
Summary of Key Data and Projections
| Aspect |
Detail |
Notes |
| Development Stage |
Completed Phase 2 trials |
No current active trials for DS or other indications |
| Regulatory Status |
No approvals |
Discontinued in primary indications |
| Estimated Peak Market |
~$1.5 billion |
Primary focus on cognitive deficits in DS; unlikely to reach full potential without renewed development |
| Patent Life |
Expires ~2030 |
Potential for extension if patents are maintained |
| Competitors |
Multiple neurocognitive agents |
Greater pipeline uncertainty |
Key Takeaways
- Basmisanil has completed Phase 2 development for Down syndrome but failed to demonstrate efficacy.
- Roche has halted development for primary indications, constraining commercial prospects.
- Future market growth depends on new indications, partnerships, or improved derivatives.
- The drug's patent protections extend until around 2030, offering a window for potential repositioning.
- The competitiveness of Basmisanil diminishes unless new clinical evidence supports alternative uses.
FAQs
1. What was Basmisanil developed for?
It aimed to treat cognitive deficits, especially in Down syndrome, by modulating the GABA-A receptor alpha-5 subtype.
2. Why was development halted?
Clinical trials did not show statistically significant improvements, leading Roche to discontinue further development for DS.
3. Can Basmisanil be repurposed for other conditions?
Repositioning depends on emerging evidence; currently, no active trials or announced plans target new indications.
4. When do patent protections lapse?
Patents are expected to expire around 2030, assuming no extensions.
5. What are the prospects for similar drugs in this space?
Other GABA-A receptor modulators and neurocognitive agents are in development, though none have cleared as effective as hoped for these indications.
Citations
[1] Roche. (2018). Clinical trial results on Basmisanil in Down syndrome.
[2] ClinicalTrials.gov. (latest trial status for Basmisanil).
[3] Market Data. (Industry reports on neurodevelopmental disorder therapeutics).
